UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

July 5, 2006

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

13200 Progress Boulevard

Alachua, Florida 32615

(Address of principal executive offices including zip code)

(386) 418-4018

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Item 3.02 UNREGISTERED SALES OF EQUITY SECURITIES.

On July 5, 2006, Oragenics, Inc. (the “Company”) announced that 1,046,606 warrants to purchase common stock previously issued by the Company were exercised by four warrant holders, including Company Director George Hawes, resulting in aggregate proceeds to the Company of $600,000. As previously reported by the Company on Form 8-K, the private placement offering and sale of the warrants was made in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933.

A copy of the July 5, 2006 press release announcing the exercise of the warrants is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 8.01 OTHER EVENTS.

On July 5, 2006, the Company issued a press release announcing the exercise of warrants, its financial position as a result of the receipt of aggregate proceeds of $600,000 in connection with the exercise and its current burn rate. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

(d) Exhibits.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.